Clora highlights ARPA-H funding for distributed RNA manufacturing
ARPA-H invests $125 million to scale personalized RNA therapies via decentralized production networks.
See the latest news and media coverage for Clora. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life sciences talent marketplace
clora.comLast updated
In short: Clora highlighted key biotech milestones, including a $125M ARPA-H investment for RNA therapies and Orca Bio's FDA cell therapy approval.
ARPA-H invests $125 million to scale personalized RNA therapies via decentralized production networks.
The XBI index has nearly doubled, driving a shift in the funding environment and prompting teams to carefully consider resourcing strategies for upcoming work.
Moderna and Merck's Intismeran hits Phase 3 primary endpoint for melanoma. This marks the first randomized Phase 3 validation of personalized cancer vaccines.
Spero secures exclusive license for SP001 and $105M financing to extend its cash runway into late 2029.
Clora is building the future of work in the life sciences. By combining the two companies, Clora will continue to expand its global talent operations...
PALO ALTO, Calif. & BOSTON--(BUSINESS WIRE)--Science Exchange, the world’s leading marketplace for outsourced R&D™, today announced a strategic partnership with Clora, a technology platform that...
On-demand labor marketplaces have been around for decades on the internet. Paying someone to identify a cat using Amazon Mechanical Turk or hiring someone to...
It often takes about 14 years and $2 billion to develop a drug and get it into the hands of doctors and patients. However, a...
Track Clora and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Clora and other trending companies.